Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06722417 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06722417 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 16 participants.
The verdict
NCT06722417, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.
Interventions
- DRUG Icalcaprant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06722417
The ClinicalTrials.gov registry entry for NCT06722417 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Icalcaprant is the first listed.
NCT06722417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06722417 about?
NCT06722417 is a clinical study titled "A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants". This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.
What is the current status of trial NCT06722417?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2024-11-26. Estimated completion is 2025-01-17.
What interventions are being tested in trial NCT06722417?
The interventions under investigation include: Icalcaprant (DRUG).
Who is sponsoring clinical trial NCT06722417?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.